The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients.


Journal

Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897

Informations de publication

Date de publication:
26 Apr 2024
Historique:
received: 24 10 2023
accepted: 29 12 2023
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti-β In this single center retrospective cohort study, based on the screening of our pediatric (age ≤ 18) rheumatology electronic medical records (2016-2022), we identified patients who had at least one "positive" aPL (lupus anticoagulant [LA], aCL IgG/M, or aβ An initial high-risk aPL profile was persistent in approximately 90% of our cohort, a third of whom had thrombosis, and half had non-thrombotic aPL manifestations. Our results underscore the need for a large-scale effort to better characterize aPL-related manifestations in pediatric patients with persistent high-risk aPL-profiles.

Sections du résumé

BACKGROUND BACKGROUND
The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti-β
FINDINGS RESULTS
In this single center retrospective cohort study, based on the screening of our pediatric (age ≤ 18) rheumatology electronic medical records (2016-2022), we identified patients who had at least one "positive" aPL (lupus anticoagulant [LA], aCL IgG/M, or aβ
CONCLUSION CONCLUSIONS
An initial high-risk aPL profile was persistent in approximately 90% of our cohort, a third of whom had thrombosis, and half had non-thrombotic aPL manifestations. Our results underscore the need for a large-scale effort to better characterize aPL-related manifestations in pediatric patients with persistent high-risk aPL-profiles.

Identifiants

pubmed: 38671480
doi: 10.1186/s12969-024-00954-8
pii: 10.1186/s12969-024-00954-8
doi:

Substances chimiques

Antibodies, Antiphospholipid 0
beta 2-Glycoprotein I 0
Antibodies, Anticardiolipin 0
Lupus Coagulation Inhibitor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46

Informations de copyright

© 2024. The Author(s).

Références

Avčin T. Antiphospholipid syndrome in children. Curr Opin Rheumatol. 2008;20(5):595–600. https://doi.org/10.1097/BOR.0B013E3283060A8C .
doi: 10.1097/BOR.0B013E3283060A8C pubmed: 18698184
Garcia D, Erkan D. Diagnosis and management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010–21. https://doi.org/10.1056/nejmra1705454 .
doi: 10.1056/nejmra1705454 pubmed: 29791828
Avčin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5). https://doi.org/10.1542/peds.2008-1209 .
Soybilgic A, Avcin T, Pediatric APS. State of the Art. Published online 2020. https://doi.org/10.1007/s11926-020-0887-9 .
Sevim E, Zisa D, Andrade D, et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2022;74(2):324–35. https://doi.org/10.1002/acr.24468 .
doi: 10.1002/acr.24468 pubmed: 32986935
Barbhaiya M, Taghavi M, Zuily S et al. Efforts to Better Characterize Antiphospholipid Antibody Nephropathy for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. J Rheumatol. Published online September 1, 2023:jrheum.2022– 1200. https://doi.org/10.3899/JRHEUM.2022-1200 .
Barbhaiya M, Zuily S, Naden R et al. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis and Rheumatology. Published online 2023. https://doi.org/10.1002/art.42624 .
Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93(6):1147–52. https://doi.org/10.1160/TH04-12-0839/ID/JR0839-1/BIB .
doi: 10.1160/TH04-12-0839/ID/JR0839-1/BIB pubmed: 15968401
Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford). 2015;54(11):2071–5. https://doi.org/10.1093/RHEUMATOLOGY/KEV238 .
doi: 10.1093/RHEUMATOLOGY/KEV238 pubmed: 26163690
Rozic M, Trampus-Bakija A, Rener-Primec Z, Kitanovski L, Kveder T, Avcin T. PReS-FINAL-2349: Spectrum of thrombotic and non-thrombotic manifestations in 159 children with positive antiphospholipid antibodies. Pediatric Rheumatology 2013 11:2. 2013;11(2):1–2. https://doi.org/10.1186/1546-0096-11-S2-P339 .
Avčin T, Cimaz R, Rozman B, et al. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9. https://doi.org/10.1177/0961203309106917 .
doi: 10.1177/0961203309106917 pubmed: 19671789
Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric Antiphospholipid Syndrome. Published online 2015. https://doi.org/10.1007/s11926-015-0504-5 .
Cervera R, Piette JC, Font J, et al. Antiphospholipid Syndrome Clinical and immunologic manifestations and patterns of Disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27. https://doi.org/10.1002/art.10187 .
doi: 10.1002/art.10187 pubmed: 11953980
Rumsey DG, Myones B, Massicotte P. Diagnosis and treatment of antiphospholipid syndrome in childhood: a review. Blood Cells Mol Dis. 2017;67:34–40. https://doi.org/10.1016/J.BCMD.2017.02.009 .
doi: 10.1016/J.BCMD.2017.02.009 pubmed: 28283251
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. https://doi.org/10.1111/J.1538-7836.2006.01753.X .
doi: 10.1111/J.1538-7836.2006.01753.X pubmed: 16420554
Wincup C, Ioannou Y. The differences between childhood and adult onset antiphospholipid syndrome. Front Pediatr. 2018;6(November):1–10. https://doi.org/10.3389/fped.2018.00362 .
doi: 10.3389/fped.2018.00362

Auteurs

Jheel Pandya (J)

Department of Pediatric Rheumatology, Hospital for Special Surgery, 535 E 70th Street, 10021, New York, NY, USA. pandyaj@hss.edu.

Karen Onel (K)

Department of Pediatric Rheumatology, Hospital for Special Surgery, 535 E 70th Street, 10021, New York, NY, USA.

Doruk Erkan (D)

Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Disease, Weill Cornell Medicine, 535 E70th Street, 10021, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH